Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by ITM Isotope Technologies Munich SE

< Previous 1 2 Next >
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Annette Breunig as Chief People Officer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
Barbara Weber, M.D., Elected to ITM Supervisory Board
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Celine Wilke as Chief Medical Officer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces Updates to Commercial Leadership
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at Raymond James Private Biotech Symposium
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Participate in Upcoming Investor Conferences
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.